Enhanced in vivo antitumor survival in anti-CD69–treated mice. Survival profiles of C57BL/6 mice treated with mAb CD69.2.2 or with control isotype are shown. The C57BL/6 mice were inoculated intraperitoneally with 105 RMA-S cells and treated with 1 single dose (500 μg mAb), either 1 day before (A, ▪) or 1 (▪), 3 (▾), or 5 days (♦) after (B) inoculation with RMA-S cells. □ indicates control. C57BL/6 mice (C) were treated (500 μg mAb) 4, 8, and 12 days after inoculation subcutaneously with 105 RMA-S cells. C57BL/6 mice (D) were injected intravenously with 104 RM-1 cells and were treated with 1 dose (500 μg) of mAb CD69.2.2 or isotype control mAb either on day 1 or 5 after tumor challenge. (i) Number of lung metastases was counted 16 days after tumor inoculation. Each symbol represents 1 mouse: ○ indicates control mAb; •, mAb CD69.2.2. Photographs are of lungs from mAb CD69.2.2 (+1 day) (iii) or control mAb–treated mice (ii). (A, n = 7; B, n = 5; C, n = 5; D, n = 9). Panels A-C show 1 of 2 independent experiments. Panel D combines the results from 2 independent experiments. The mean number of lung metastases is represented by horizontal bars.
